Advertisement

Journal of Neuro-Oncology

, Volume 10, Issue 1, pp 57–74 | Cite as

Interstitial chemotherapy for brain tumors: review

  • T. Tomita
Clinical Study

Abstract

An extensive effort to search for curative chemotherapeutic approaches has found no ‘breakthrough’ in management of patients with malignant brain tumors. Despite the trials with new agents or protocols of multiple agents, systemic chemotherapy has failed to provide reliable clinical response. Interstitial chemotherapy has been practiced for malignant brain tumors with administering chemotherapeutic compounds directly into the tumor which provide increased and prolonged drug concentration in the tumor, reduction of systemic toxicity and bypassing the blood-brain barrier. These theoretical advantages encourage further pursuing interstitial chemotherapy for patients with malignant brain tumors who would otherwise be always fatal.

In this review, the literature has been reviewed to identify methods toxicity and efficacy of interstitial chemotherapy. Clinical and experimental data indicate limited toxicity and promising efficacy. Various methods to administer the agents were utilized; intraoperative topical application, local injections through catheters or implantable controlled drug delivery system. Selection of ideal chemotherapeutic agents and development of drug delivery system need further investigations.

Key words

brain neoplasm chemotherapy drug delivery system intraneoplastic injection 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kornblith PL, Walker gnT. M: Chemotherapy for malignant gliomas. J Neurosurg 68: 1–17, 1988Google Scholar
  2. 2.
    Shapiro WR, Shapiro JR: Principles of brain tumor chemotherapy. Seminars in Oncology 13: 56–69, 1986Google Scholar
  3. 3.
    Vick NA, Khandeker JD, Bigner DD: Chemotherapy of brain tumors. The ‘blood-brain barrier’ is not a factor. Arch Neurol 34: 523–526, 1977Google Scholar
  4. 4.
    Rall DP, Zubrod CG: Mechanisms of drug absorption and excretion; passage of drugs in and out of the central nervous system. Ann Rev Pharmacol 2: 109–128, 1962Google Scholar
  5. 5.
    Levin VA, Freeman-Dove M, Landahl HD: Permeability characteristics of brain adjacent to tumors in rats. Arch Neurol 32: 785–791, 1975Google Scholar
  6. 6.
    Blasberg RG, Goothuis DR: Chemotherapy of brain tumors; physiological and pharmacokinetic consideration. Seminar in Oncology 13: 70–82, 1986Google Scholar
  7. 7.
    Levin VA, Patlak CS, Landahl HD: Heuristic modeling of drug delivery to malignant brain tumors. J Pharmacokinet Biopharm 8:257–296,1980Google Scholar
  8. 8.
    Hoshino T, Barker M, Wilson CB, Boldrey EB, Fewer D: Cell kinetics of human gliomas. J Neurosurg 37:15–26,1972Google Scholar
  9. 9.
    Shapiro WR, Green SB: Reevaluating the efficacy of intra-arterial BCNU. J Neurosurg 66: 313–315, 1987Google Scholar
  10. 10.
    Burger PC, Heintz ER, Shibata T, Kleihues P: Topographic anatomy and correlations in the untreated glioblastoma multiforme. J Neurosurg 68: 698–704, 1988Google Scholar
  11. 11.
    Heppner F, Diemath HE: Local chemotherapy of brain tumors. Acta Neurochir 11: 287–293, 1963Google Scholar
  12. 12.
    Ringkjob R: Treatment of intracranial gliomas and metastatic carcinomas by local application of cytostatic agents. Acta Neurol Scand 44: 318–322, 1968Google Scholar
  13. 13.
    Diemath HE: Local application of cytostatic drugs after removal of glioblastomas. Wiener Klinische Wochenschrift 99:674–676,1987Google Scholar
  14. 14.
    Bateman JC: Chemotherapy of solid tumors with triethyl phosphoramide. New England J Med 252: 879–887, 1955Google Scholar
  15. 15.
    Rubin RC, Ommaya AK, Henderson ES, Bering EA, Rall DP: Cerebrospinal fluid perfusion for central nervous system neoplasms. Neurology 16: 680–692, 1966Google Scholar
  16. 16.
    Weiss SR, Raskind R: Treatment of malignant brain tumors by local methotrexate; a preliminary report. Int Surg 51:149–155, 1969Google Scholar
  17. 17.
    Hayakawa T, Yamada R, Kanai N, Kuroda R, Ushio Y, Higashi H, Mogami H: Intrathecal chemotherapy. Selection of cytostatic agents. Br J Cancer 24: 489–497, 1970Google Scholar
  18. 18.
    Garfield J, Dayan AD: Postoperative intracavitary chemotherapy of malignant gliomas, preliminary study using methtrexate. J Neurosurg 39: 315–322, 1973Google Scholar
  19. 19.
    Garfield J, Dayan AD, Weller RO: Postoperative intracavitary chemotherapy of malignant supratentorial astrocytomas using BCNU. Clinical Oncology 1: 213–222, 1975Google Scholar
  20. 20.
    Kubo O, Takakura K, Miki Y, Okino T, Kitamura K: Intracystic therapy of bleomycin for craniopharyngioma —effect of bleomycin for cultured cramopharyngioma cells and intracystic concentration of bleomycin. No Shinkei Geka 2: 683–689, 1974Google Scholar
  21. 21.
    Ohwaki K, Nakazawa S, Yajima K, Shimura T: Treatment of brain tumor by local injection of bleomycin. The VIth International Congress. Excerpta Medica 418198, 1977Google Scholar
  22. 22.
    Bosch DA, Hindmarsh Th, Larsson St, Backlund E-O: Intraneoplastic administration of bleomycin in intracerebral gliomas: a pilot study. Acta Neurochirur (suppl) 30: 441–444,1980Google Scholar
  23. 23.
    Nakazawa S, Ohwaki K, Shimura T, Itoh Y, Yajima K: A new treatment of malignant brain tumor-1. local injection of bleomycin. No Shinkei Geka 9: 1487–1493, 1981Google Scholar
  24. 24.
    Shimura T, Nakazawa S: Intraneoplastic loca injection of adriamycin for malignant brain tumor chemotherapy — a clinicopathological study. No Shinkei Geka 8: 35–42, 1980Google Scholar
  25. 25.
    Nakazawa S, Itoh Y, Shimura T, Matsumoto M, Yajima K: A new treatment of malignant brain tumors — 2. local injection of adriamycin. No Shinkei Geka 11: 821–827, 1983Google Scholar
  26. 26.
    Takahashi H, Nakazawa S, Shimura T: Evaluation of postoperative intratumoral injection of bleomycin for craniopharyngioma in children. J Neurosurg 62: 120–127, 1985Google Scholar
  27. 27.
    Morantz RA, Kimler BF, Vats TS, Henderson SD: Bleomycin and brain tumors. A review. J Neurooncology 1: 249–255,1983Google Scholar
  28. 28.
    Uemura S, Matsukado Y, Kuratsu J, Sonoda H, Ohtsuka T, Yoshioka S, Yamada M: Local chemotherapy of malignant glioma. Intra-tumoral administration of neocarzinostatin. Neurol Med Chir (Tokyo) 26: 468–474, 1986Google Scholar
  29. 29.
    Bouvier G, Penn RD, Kroin JS, Beique R, Guerard MJ: Direct delivering of medication into a brain tumor through multiple chronically implanted catheters. Neurosurgery 20: 286–291,1987Google Scholar
  30. 30.
    Oda Y, Kamijto Y, Okumura T, Tokuriki Y, Yamashita J, Handa H, Aoyama I, Hashi K, Mori K: Clinical application of a sustained release anticancer pellet. No Shinkei Geka 13:1305–1311,1985Google Scholar
  31. 31.
    Oda Y, Uchida Y, Murata T, Mori K, Tokuriki Y, Handa H, Kobayashi A, Hashi K, Kieler J: Treatment of brain tumors with anticancer pellet — experimental and clinical study. No Shinkei Geka 10: 375–381, 1982Google Scholar
  32. 32.
    Kubo O, Himuro H, Inoue T, Tajima T, Tohyama T, Sakairi M, Kitamura K: Treatment of malignant brain tumors with slowly releasing anticancer drug-polymer composites. No Shinkei Geka 14: 1189–1195, 1986Google Scholar
  33. 33.
    Katakura R, Mori T, Suzuki J: A device for prolonged releasing of anticancer drug -bleomycin: second report. No Shinkei Geka 10: 1057–1062,1982Google Scholar
  34. 34.
    McKeran RO, Firth G, Oliver S, Uttley D, O'Laioire S: A potential application for the intracerebral injection of drugs entrapped within liposomes in the treatment of human cerebral gliomas. J Neurol Neurosurg Psychiat 48: 1213–1219, 1985Google Scholar
  35. 35.
    Ito H, Hasegawa T, Shoin K, Hwang W-Z, Hayashi M, Yamamoto S, Miyazaki I: Necrectomy of brain stem glioma and local administration anticancer agents. No Shinkei Geka 13:1053–1057,1985Google Scholar
  36. 36.
    Tator CH, Wassenaar W: Intraneoplastic injection of methotrexate for experimental brain tumor chemotherapy. J Neurosurg 46: 165–174, 1977Google Scholar
  37. 37.
    Tator CH: Intraneoplastic injection of CCNU for experimental brain tumor chemotherapy. Surg Neurol 7: 73–77, 1977Google Scholar
  38. 38.
    Vats TS, Morantz RA, Wood GW, Tilzer S: Study of effectiveness of bleomycin in rat brain tumor model intravenously and intracerebrally. Int J Radiat Oncol Biophy 5: 1527–1529, 1979Google Scholar
  39. 39.
    Katakura R, Mori T, Mineura K, Suzuki J: A device for prolonged releasing of anticancer drug — bleomycin. No Shinkei Geka 8: 1057–1062,1980Google Scholar
  40. 40.
    Steel GG: Growth kinetics of brain tumors. In: Thomas DGT, Graham DI (eds), 1980, Brain Tumours, Scientific Basis, Clinical Investigations and Current Therapy. Butterworths, London. pp 10–20Google Scholar
  41. 41.
    Rama B, Mandel T, Jansen E, Dingeldein E, Mennel HD: The intraneoplastic chemotherapy in a rat brain tumour model utilizing methotrexate-polymethylmethacrylate-pellets. Acta Neurochir (Wien) 87: 70–75, 1987Google Scholar
  42. 42.
    Kroin JS, Penn RD: Intracerebral chemotherapy: chronic microperfusion of cisplatin. Neurosurgery 10: 349–354, 1982Google Scholar
  43. 43.
    Sendelbeck SL, Urquhart J: Spatial distribution of dopamine, methotrexate and antipyrine during continuous intracerebral microperfusion. Brain Res 328: 251–258, 1985Google Scholar
  44. 44.
    Liu HS, Refojo MF, Perry HD, Albert DM: Sustained release of BCNU for the treatment of intraocular malignancies in animal models. Invest Ophthalmol Visual Sci 18: 1061–1067,1979Google Scholar
  45. 45.
    Firth G, Oliver AS, McKeran RO: Studies on the intracerebral injection of bleomycin free and entrapped within liposomes in the rat. J Neurol Neurosurg Psychiat 47: 585–589, 1984Google Scholar
  46. 46.
    Oliver AS, Firth G, McKeran RO: Studies on the intracerebral injection of vincristine free and entrapped within liposomes in the rat. J Neurol Sci 68: 25–30, 1985Google Scholar
  47. 47.
    Hong F, Mayhew E: Therapy of central nervous system (CNS) mouse leukemia by liposome-entrapped 1-beta-arabinofuranosylcytosine (Lip-Ara-C). Proc Annu Meet Am Assoc Cancer Res 29: A2018, 1988Google Scholar
  48. 48.
    Penn RD, Kroin JS, Harris JE, Chiu KM, Braun DP: Chronic intratumoral chemotherapy of a rat tumor with cisplatin and fluorouracil. App Neurophysiol 46: 240–244, 1983Google Scholar
  49. 49.
    Sutton R, Conley F, Yu N, Brown D: Matrix associated chemotherapy for the localized treatment of experimental murine brain tumors. Proc Annu Meet Am Assoc Cancer Res 29: A2014, 1988Google Scholar
  50. 50.
    Tamargo RJ, Epstein JI, Yang MB, Pinn ML, Chasin M, Brem H: Interstitial vs. systemic chemotherapy of the intracranial 9L gliosarcoma: controlled-release polymers for local therapy. Presented at the Annual Meeting of the American Association of Neurological Surgeons, Washington, D.C., April 3, 1989Google Scholar
  51. 51.
    Ausman JI, Levin VA, Brown WE, Rall DP, Fenstermacher JD: Brain-tumor chemotherapy. Pharmacological principles derived from a monkey brain-tumor model. J Neurosurg 46: 155–164, 1977Google Scholar
  52. 52.
    Bakay L: The extracellular space in brain tumours. I. Morphological consideration. Brain 93: 693–698, 1970Google Scholar
  53. 53.
    Bakay L: The extracellular space in brain tumours. II. The surface space. Brain 93: 699–708, 1970Google Scholar
  54. 54.
    Blasberg RG, Patlak C, Fenstermacher JD: Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 195: 73–83, 1975Google Scholar
  55. 55.
    Blasberg RG, Methotrexate, cytosine arabinoside and BCNU concentration in brain after ventriculocisternal perfusion. Cancer Treat Rep 61: 625–631, 1977Google Scholar
  56. 56.
    Kaplan RS, Wiernik PH: Neurotoxicity of antineoplastic drugs. Seminars in Oncology 9: 103–130, 1982Google Scholar
  57. 57.
    Dewys WD, Fowler EH: Report of vasculitis and blindness after intracarotid injection of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU;NSC-409962) in dogs. Cancer Chemothr Rep 57: 33–40, 1973Google Scholar
  58. 58.
    Neuwelt EA, Glasberg M, Frenkel E, Barnett P: Neurotoxicity of chemotherapeutic agents after blood-brain barrier modification: neuropathological studies. Ann Neurol 14: 316–324,1983Google Scholar
  59. 59.
    Hayakawa T, Ushio Y, Morimoto K, Hasegawa H: Uptake of bleomycin by human brain tumours. J Neurol Neurosurg Psychiat 39:341–349,1976Google Scholar
  60. 60.
    Mark VH, Kjellberg RN, Ojeman RG, Soloway AH: Treatment of malignant brain tumors with alkylating agents. Thio-TEPA (triethylene thiophosphoramide): its differential concentration and toxicity after arterial infusion. Neurology 10: 772–776,1960Google Scholar
  61. 61.
    Tator CH, Wassenaar W, Day A, So WS: Therapy of an experimental glioma with systemic or intraneoplastic methotrexate or radiation. J Neurosurg 46: 175–184, 1977Google Scholar
  62. 62.
    Shimura T, Nakazawa S, Itoh Y, Kobayashi S, Satoh S, Aihara K: Intraneoplastic local injection of adriamycin for the treatment of experimental brain tumor — an autoradiographic study. No Shinkei Geka 9: 799–806, 1981Google Scholar
  63. 63.
    Merker PC, Lewis MR, Walker MD, Richardson EP Jr: Neurotoxicity of adriamycin (doxorubicin) perfused through the cerebrospinal fluid spaces of the rhesus monkey. Toxicol App Pharmacol 44: 191–205, 1978Google Scholar
  64. 64.
    Bagdahn U: Chemosensitivity of malignant human brain tumors. J Neuro-oncology 1: 149–166, 1983Google Scholar
  65. 65.
    Kimmel DW, Shapiro JR, Shapiro WR: In vitro drug sensitivity testing in human gliomas. J Neurosurg 66: 161–171, 1987Google Scholar
  66. 66.
    Friedman HS, Schold SC, Muhlbaiter LH, Bjornsson TD, Bigner DD: In vitro versus in vivo correlations of chemosensitivity of human medulloblastoma. Cancer Res 44: 5145–5149,1984Google Scholar
  67. 67.
    Takagi H, Marmarou A: Study of brain edema by infusion edema model — biophysical changes of white mater for the movement of edema fluid. No Shinkei Geka 11: 1141–1146, 1983Google Scholar
  68. 68.
    Heller J: Use of polymers in controlled release of active agents. In Robinson JR, Lee VHL (eds). Controlled Drug Delivery. Fundamentals and Applications. 1987, Mercel Dekker, New York and Basel, pp 180–212Google Scholar
  69. 69.
    Garrett ER, Chemburkar PB: Evaluation, control, and prediction of drug diffusion through polymetric membrane II. diffusion of aminophenes through silastic membrane; a test of the pH-partition hypothesis. J Pharm Sci 57: 949–956, 1968Google Scholar
  70. 70.
    Beck PE, Musante LA: In overview of the FDA approved controlled-release polymetric materials. Proceed Intern Sym Control Rel Bioact Mater 12: 214, 1985Google Scholar
  71. 71.
    Garrett ER, Chemburka PB: Evaluation, control, and prediction of drug diffusion through polymetric membrane III. Diffusion of barbiturates, phenylalkylamines, dextromethorphan, progesterone, and other drugs. J Pharm Sci 57: 1401–1409,1968Google Scholar
  72. 72.
    Folkman J, Long DM: The use of silicone rubber as a carrier for prolonged drug therapy. J Surg Res 4: 139–142, 1964Google Scholar
  73. 73.
    Baker R: Controlled Release of Biologically Active Agents. 1987 John Wiley, New York, pp 156–157Google Scholar
  74. 74.
    Sundaram K, Kincl FA: Sustained release hormonal preparations. 2. factors controlling the diffusion of steroids through dimethylpolysiloxane membranes. Steroids 12: 517–524,1968Google Scholar
  75. 75.
    Frick J, Kincl FA: Applications in Cancer. In Langer RS, Wise DL (eds). Medical Application of Controlled Release. Vol 2. Application and Evaluation. 1984, CRC, Boca Raton, pp 140–148Google Scholar
  76. 76.
    Dziuk PJ, Cook B: Passage of steroids through silicone rubber. Endocrinology 78: 208–211, 1966Google Scholar
  77. 77.
    Oda Y, Kamijyo Y, Kang Y, Okumura T, Tokuriki Y, Handa H: Evaluation of the sustained release of anticancer agents from silicone pellets. J Jpn Soc Cancer Ther 20: 2236–2242,1985Google Scholar
  78. 78.
    Oda Y, Uchida Y, Nakano S, Yamashita J, Takeuchi J, Handa H: Constant release of fluorouracil embedded in silastic. J Jpn Soc Cancer Ther 13: 126–132, 1978Google Scholar
  79. 79.
    Oda Y, Uchida Y, Tokuriki Y, Handa H, Akashi S, Murakami N, Kadowaki T, Kinoshita D, Kieler J: Synergistic effect of urokinase with 5-fluorouracil embedded in silicone elastomer; in vivo observation in rat neurogenic tumors induced by ethylnitrosourea. Gan TO Kagaku Rhyoho 5: 1293–1300,1978Google Scholar
  80. 80.
    Rosenblum ML, Bowie DL, Walker MD: Diffusion in vitro and in vivo of 1-(2-chlorethyl)-3-(trans-4-methylcyclo-hexyl)-1-nitrosourea from silicone rubber capsules, a potentially new mode of chemotherapy administration. Cancer Res 33: 906–914, 1973Google Scholar
  81. 81.
    Schmidt V, Zapol W, Wonders T, Wodinsky I, Kitz R: Continuous cancer chemotherapy: nitrosourea diffusion through implanted silicone rubber capsule. Trans Am Soc Artif Intern Organs 18: 45–53, 1972Google Scholar
  82. 82.
    Ueno N, Refojo MF, Liu LHS: Controlled release rate of a lipophilic drug (BCNU) from a refillable silicone rubber device. J Biomedical Material Research 16: 669–677, 1982Google Scholar
  83. 83.
    Wilkinson HA, Kornblith P, Weems S: Focal chemotherapy of brain tumours using semipermeable membranes. J Neurol Neurosurg Psychiat 40: 389–394, 1977Google Scholar
  84. 84.
    Oda Y, Tokuriki Y, Tsuda E, Handa H, Kieler J: Trial of anticancer pellet in malignant brain tumours; 5-FU and urokinase embedded in silastic. Acta Neurochirur (suppl) 28:489–490,1979Google Scholar
  85. 85.
    Kincl FA, Benagiano G, Angee I: Sustained release hormonal preparations. Steroids 11: 673–680, 1968Google Scholar
  86. 86.
    Wahlig H, Dingeldein E, Bergman E, Reuss K: The release of gentamycin from polymethylmethacrylate beads. An experiment and pharmacokinetic study. J Bone Joint Surg 60-B: 270–275,1978Google Scholar
  87. 87.
    Kato T, Nemoto R, Mori H, Takahashi M, Tamakawa Y, Harada M: Arterial chemoembolization with microencapsulated anticancer drug, an approach to selective cancer chemotherapy with sustained effects. JAMA 245: 1123–1127, 1981Google Scholar
  88. 88.
    Szoka F, Paphadjopoulos D: Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Matl Acad Sci 75: 4194–4198,1978Google Scholar
  89. 89.
    Firth G, Oliver AS, McKeran RO: Studies on the use of antimiotic drugs entrapped within liposomes and of their action on a human glioma cell line. J Neurol Sci 63:153–165, 1984aGoogle Scholar
  90. 90.
    Leong KW, Brott BC, Langer R: Bioerodible poly anhydrides as drug-carrier materials. I; characterization, degradation, and release characteristics. J Biomed Materials Res 19: 941–955, 1985Google Scholar
  91. 91.
    Leong KW, O'Amore P, Marletta M, Langer R: Bioerodible polyanhydrides as drug-carrier matrices. II; biocompatibility and chemical reactivity. J Biomed Materials Res 20:51–64,1986Google Scholar
  92. 92.
    Rosen HB, Chang J, Wnek GE, Linhardt RJ, Langer: Bioerodible polyanhydrides for controlled drug delivery. Biomaterials 4: 131–133, 1983Google Scholar
  93. 93.
    Oda Y, Uchida Y, Tokuriki Y, Handa H, Akashi S, Murakami N, Kadowaki T, Kinoshita D: Constant release and stability of macromolecule (urokinase) in silicone elastomer. Gan TO Kagaku Ryoho 5: 1287–1292, 1978Google Scholar
  94. 94.
    Hamada M, Asakura T: Effects of corticosteroids on malignant brain tumors: experimental studies and clinical intratumoral injection of corticosteroids. Neurochirur (Stuttg) [suppl] 364, 1981Google Scholar
  95. 95.
    Sasahira M, Ichitubo H: Intratumoral chemotherapy for gliomas and metastatic brain tumor. A clinicopathological study. Neurochirur (Stuttg) [suppl] 363, 1981Google Scholar
  96. 96.
    Refojo MF, Liu HS, Leong F-L, Sidebottom D: Release of a nitrosourea derivative from refillable silicone rubber implants for the treatment of intraocular malignancies. J Bioengineering 2: 437–445, 1978Google Scholar

Copyright information

© Kluwer Academic Publishers 1991

Authors and Affiliations

  • T. Tomita
    • 1
    • 2
  1. 1.Division of Pediatric NeurosurgeryChildren's Memorial HospitalChicagoUSA
  2. 2.Northwestern University Medical SchoolChicagoUSA

Personalised recommendations